Jonah Kirkwood, Agilent’s chief commercial officer, emphasized the company’s focus on high-growth markets and its dedication to partnering closely with customers to address their changing needs.

On May 29, analyst Michael Ryskin from Bank of America Securities reiterated a Hold rating on Agilent Technologies Inc ...

Q2 2025 Earnings Call Transcript May 28, 2025 Agilent Technologies, Inc. beats earnings expectations. Reported EPS is $1.31, ...

The firm's diagnostics and life sciences revenues jumped 8 percent, and Agilent raised its full-year guidance on expectations of 3 to 5 percent growth.

A's second-quarter fiscal 2025 results benefit from strong LC & services, but margin contraction raises investor concerns.

Agilent Technologies Inc. (NYSE:A) reported second-quarter 2025 sales of $1.67 billion on Wednesday, almost in line with the ...

Agilent's Morningstar Uncertainty Rating remains Medium, thanks to its sticky end markets that should result in relatively steady demand trends in the long run, despite its dependence on one-time ...

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

Discover Agilent's strong Q2 2025 performance with 6% revenue growth, Ignite-driven cost savings, and proactive tariff mitigation.

Agilent Technologies beat Wall Street estimates for second-quarter profit and revenue on Wednesday, helped by strong demand for its tools and equipment used in drug development, sending its shares up ...

The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid ...

Joining in the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelika Reimann, President of the Agilent CrossLab Group, and Mike Zhang, President of the Applied ...